Chinese inhibitor drug candidate becomes first to enter phase
Time:2024-05-21 12:56:02 Source:politicsViews(143)
Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312.
SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally.
The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations.
The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy.
Previous:Rangers are undefeated at .500 to keep World Series champs from a losing record with Bochy
Next:Biden says Brown v. Board of Education ruling was about more than education
You may also like
- French sports minister calls for sanctions after Monaco player tapes over anti
- Former world's oldest dog stripped of title
- Nearly half of the world’s migratory species are in decline, UN report says
- Pharmacists now permitted to vaccinate children under 5
- Pope trip to Luxembourg, Belgium confirmed for September, 2 weeks after challenging Asia visit
- Benefit sanctions to ramp up with 'work check
- Swedish appeals court rules space rock should stay with the owner of the property where it landed
- Airplane passenger fined in Sydney for urinating in a cup
- Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers